Cefazolin Prophylaxis for Total Joint Arthroplasty: Obese Patients are Frequently Underdosed and at Increased Risk for Periprosthetic Joint Infection

Running Title: Cefazolin Dosing in TJA

Alexander J. Rondon, MD, MBA¹

Michael M. Kheir, MD²

Timothy L. Tan, MD¹

Noam Shohat, MD^{1,3}

Max R. Greenky, MD¹

Javad Parvizi, MD, FRCS¹

¹The Rothman Institute at Thomas Jefferson University, Philadelphia, PA 19107

²Department of Orthopaedics at Indiana University, Indianapolis, IN 46202

³Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel

Corresponding Author:

Javad Parvizi, MD, FRCS

The Rothman Institute

125 S 9th St. Ste 1000

Philadelphia, PA 19107

P: 267-339-7813

F: 215-503-5651

parvj@aol.com

This is the author's manuscript of the article published in final edited form as:

Rondon, A. J., Kheir, M. M., Tan, T. L., Shohat, N., Greenky, M. R., & Parvizi, J. (2018). Cefazolin Prophylaxis for Total Joint Arthroplasty: Obese Patients are Frequently Underdosed and at Increased Risk for Periprosthetic Joint Infection. *The Journal of Arthroplasty*. <https://doi.org/10.1016/j.arth.2018.06.037>

1 **Cefazolin Prophylaxis for Total Joint Arthroplasty: Obese Patients are Frequently**
2 **Underdosed and at Increased Risk for Periprosthetic Joint Infection**

3 Running Title: Cefazolin Dosing in TJA
4
5

6 ABSTRACT

7 *Background:* One of the most effective prophylactic strategies against periprosthetic joint
8 infection (PJI) is administration of perioperative antibiotics. Many orthopaedic surgeons
9 are unaware of the weight-based dosing protocol for cefazolin. This study aimed to
10 elucidate what proportion of patients receiving cefazolin prophylaxis are underdosed and
11 whether this increases the risk for PJI.

12
13 *Methods:* A retrospective study of 17,393 primary total joint arthroplasties (TJA)
14 receiving cefazolin as perioperative prophylaxis from 2005-2017 was performed. Patients
15 were stratified into two groups (underdosed and adequately dosed) based on patient
16 weight and antibiotic dosage. Patients that developed PJI within 1-year following index
17 procedure were identified. A bivariate and multiple logistic regression analysis were
18 performed to control for potential confounders and identify risk factors for PJI.

19
20 *Results:* The majority of patients weighing greater than 120 kg (95.9%, 944/984) were
21 underdosed. Underdosed patients had a higher rate of PJI at 1-year compared with
22 adequately dosed patients (1.51% vs. 0.86%, $p=0.002$). Patients weighing greater than
23 120 kg had higher 1-year PJI rate than patients weighing less than 120 kg (3.25% vs.
24 0.83%, $p<0.001$). Patients who were underdosed (odds ratio (OR) 1.665, $p=0.006$) with
25 greater comorbidities (OR 1.259, $p<0.001$) were more likely to develop PJI at 1-year.

26
27 *Conclusion:* Cefazolin underdosing is common, especially for patients weighing more
28 than 120 kg. Our study reports that underdosed patients were more likely to develop PJI.

Orthopaedic surgeons should pay attention to the weight-based dosing of antibiotics in the perioperative period to avoid increasing risk for PJI.

Keywords: Total Joint Arthroplasty; Periprosthetic Joint Infection; Perioperative Antibiotics; Obesity; Dosing; Risk

INTRODUCTION

One of the most effective strategies for prevention of periprosthetic joint infection (PJI) has been the administration of perioperative antibiotics. The presence of antibiotics in the serum can eliminate the bacteria that gain access to the surgical site during total joint arthroplasty (TJA) and in turn reduce the incidence of surgical site infection [1]. Current practice is to administer first or second generation cephalosporin to all patients undergoing TJA, unless contraindicated [2]. Despite the widespread use of cefazolin as a perioperative antibiotic for TJA patients, many surgeons are unaware of cefazolin's weight-based dosing. Thus, the goals of the present study are (1) to ascertain what proportion of TJA patients receiving cefazolin are adequately dosed and (2) if under-dosing was associated with increased risk of subsequent PJI.

At our institution, the recommended dose of cefazolin has traditionally been 2 grams intravenously. Current guidelines for antimicrobial prophylaxis recommend weight-based dosing protocols starting the cefazolin dose at 1 gram (g) if a patient weighs less than 60 kilograms (kg), 2 grams if patient weights between 60 kg and 120 kg, and 3 grams if patient weight over 120 kg [2,3]. A previous study at our institution found the majority of patients receiving vancomycin as perioperative prophylaxis were underdosed according to weight-based dosage recommendations (15 milligrams/kg) [4].

Given the increasing prevalence of obesity [5,6] in the TJA population, many patients may be inadequately dosed for antibiotics. Thus, the effective drug concentration may not be met to provide bactericidal effects and subsequently may predispose patients to an increased risk for PJI. We hypothesis patients who are underdosed are at increased risk of adverse events and infection.

58

59 **MATERIALS AND METHODS**

60 After Institutional Review Board approval, a retrospective review of 24,439
61 patients undergoing primary TJA at a single institution was performed from 2005-2017.
62 All patients with primary TJA, with record of the perioperative antibiotic and dosage
63 administered were included in this study. Patients with aseptic revision TJA were
64 excluded. The perioperative antibiotic and dosage were then obtained for the patient
65 population, resulting in a cohort of 17,393 of patients receiving cefazolin as perioperative
66 prophylactic antibiotic. Patients who received other types of perioperative prophylactic
67 antibiotics (i.e. Vancomycin) other than Cefazolin were excluded from the study. Patients
68 with a history of prior infection in the same joint or unavailable antibiotic information
69 were excluded from the study. An electronic query and chart review was then performed
70 to identify demographic information, height, weight, body mass index (BMI), joint,
71 laterality, length of stay, operative time, time to incision from administration of cefazolin,
72 and Charlson comorbidities. Demographic information of the cohort is presented in Table
73 1.

74 Using the generalized dosing protocol of 1 g for patients weighing below 60 kg, 2
75 g for patients weighing between 60 kg and 120 kg, and 3 g for patients weighing 120 kg
76 or greater for cefazolin, proper dosage was calculated for each patient. These values were
77 then compared to the actual dose given to the patients at time of surgery. Patients were
78 assessed as either underdosed (< 1 g, if patient weighed between 60 kg-120 kg and was
79 given < 2 g, or if patient weighed 120 kg or more and was given < 3 g) or adequately

dosed (if appropriately dosed based on weight). Cefazolin was administered within 60 minutes of incision in all cases.

The cohort was then cross-referenced with an institutional PJI database to identify patients with PJI. We defined PJI in patients based on the International Consensus Meeting criteria[7]. A subsequent manual chart review was undertaken to verify PJI outcomes and ensure the correct joint and laterality.

The primary endpoint was to assess the incidence of 1-year PJI following TJA in patients who were underdosed versus adequately dosed.

Statistical Analysis

All statistical analyses were performed with PJI rate analyzed among the two dosing groups and by weight class. Bivariate analyses were performed to compare demographics, perioperative variables between the two dosing groups and weight class. A multivariate logistic regression model was utilized to determine risk factors for PJI based on the following: antibiotic dosing, dosing status, age, patient weight, BMI, gender, joint, length of stay, and Charlson Comorbidity index. All statistical analyses were performed using R 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria) and an alpha level of 0.05 was used to evaluate significance. All analyses were conducted with Generalized estimating equations (GEE) to account for the clustering within patients who had multiple admissions. The GEE specified a binary distribution with a logit link for analyzing the dichotomous outcomes.

RESULTS

All patients included in the study received cefazolin preoperatively within 60 minutes as the main antibiotic prophylaxis. Of the 984 patients weighing 120 kg or greater, the majority were underdosed (95.9%, 944/984). For patients weighing less than 120 kg, most were adequately dosed (88.3%, 14,497/16,409). Overall, 83.6% (14,537/17,393) of patients were adequately dosed for cefazolin prophylaxis. Of note, 0.10% (18/17,393) patients were overdosed, however, none developed PJI at 1-year and all weighed between 60 and 120 kg.

Among primary TJAs, underdosed patients had a higher rate of 1-year PJI compared with adequately dosed patients (1.51% vs. 0.86%, $p=0.002$). When stratified by weight, patients weighing greater than or equal to 120 kg had higher 1-year PJI rate than patients weighing less than 120 kg (3.25% vs. 0.83%, $p<0.001$) (Table 1).

Bivariate analysis demonstrated that patients who were underdosed (adjusted odds ratio (OR) 1.762, $p=0.002$), male (OR 1.517, $p=0.014$), those with greater comorbidities (OR 1.251, $p<0.001$), and higher weight (OR 1.025, $p<0.001$) were more likely to develop PJI within 1-year (Table 2). Following multivariate regression analyses, these trends remained significant with underdosed (OR 1.665, $p=0.006$) and patients with greater comorbidities (OR 1.259, $p<0.001$) having a higher rate of PJI at 1-year (Table 3).

DISCUSSION

The efficacy and value of perioperative antibiotics for surgical prophylaxis has been proven in the literature [8]. Recent studies have supported current universal antibiotic prophylaxis versus providing treatment based on individual comorbidities[9]. The most appropriate antibiotic therapy recommended for patients undergoing TJA is a

first or second generation cephalosporin due to its broad spectrum of action, cost effectiveness, and ability to cover both gram positive and gram negative organisms [3,10,11]. Furthermore, cephalosporins are bactericidal and have excellent distribution profiles in synovium, muscle, hematomas, and bone [12]. The current American Academy of Orthopaedic Surgeons (AAOS) guidelines recommend patients receive prophylactic antibiotics within one hour prior to surgical incisions and be discontinued within 24 hours following the end of surgery [13].

The literature has previously reported on the necessity for weight-based dosing of perioperative antibiotics. While the current guidelines from the Center for Disease Control and Prevention, World Health Organization, and National Institute for Healthcare and Excellence do not provide dosing recommendation, the Society for Healthcare Epidemiology of America and the International Consensus Meeting (ICM) on PJI strongly agreed that preoperative antibiotics weight-based dosing is valid and warranted [2,14,15,3,16]. However, for adult patients, standard antibiotic dosing remains a common practice as it is safe, effective, and conveniently avoids the need for calculations, thus reducing the potential for medication errors[17]. Different ranges for perioperative cefazolin dosing protocols has been reported from standard adult dose of 2 g [18] to weight-based dosing of 1 g for patients weighing less than 80 kg or 2 g for patients weighing greater than 80 kg [19]. The American Society of Health-System Pharmacists (ASHP) recommends a weight-based protocol of 1 g from patients weighing less than 60 kg, 2 g for patients weighing 60-120 kg, and 3 g for patients weighing 120 kg or more [3]. Our institution follows these weight-based guidelines utilizing both 60 kg and 120 kg cutoffs, however, as illustrated by the results of the present study, the majority of patient

weighing above 120 kg were underdosed by receiving 2 g of antibiotics. Similar to our 5.7% rate of patients weighing greater than 120 kg, the prevalence of extreme obesity (BMI > 40) in the United States has been reported at 7.7% [5,20]. When assuming estimates of 1,000,000 TJA performed annually and an underdosing rate of greater than 90% for the extreme obese population, fifty thousand TJA patients are likely underdosed each year [21]. Given the significant rise in obesity and morbid obesity, increased scrutiny with respect to perioperative antibiotic prophylaxis is warranted to ensure that this population is not underdosed [5,6].

The literature has previously reported on factors affecting the dosing of perioperative antibiotics, specifically patient weight. One study demonstrated that 2 g of cefazolin provided 5 hours of adequate levels of prophylactic protection for patients regardless of their BMI [18]. Edminston et al. reported on cefazolin serum concentrations in morbidly obese undergoing gastric bypass, concluding that 2 g of cefazolin may not be sufficient for patients with a BMI of 50 Kg/m² or greater [22]. A prospective randomized controlled trial (RCT) of morbidly obese patients undergoing gastroplasty reported decreased wound infection rate from 16.5% to 5.6% when cefazolin dosed was increased from 1 g to 2 g [23]. In contrast to our study, Kheir et al. found a comparable PJI rate among stratified vancomycin dosage groups (underdosed 2%, adequately dosed 2%, overdosed 2%, $p=0.995$), however reported that 64% of patients receiving vancomycin as prophylaxis were underdosed and overall patients receiving vancomycin prophylaxis were at an increased risk of PJI (OR 1.587, $p=0.048$) compared to patients receiving cefazolin prophylaxis [4]. Sharareh et al. found no difference in cefazolin concentration in trabecular bone with respect to patient weight [24]. Additionally, Manrique et al.

reported that patients undergoing total knee arthroplasty (TKA) who were underweight had a higher likelihood of surgical site infection compared to other weight groups [25]. However, we do recognize that the majority of these studies report results by BMI as opposed to weight, which may create confusion as dosing is based on weight not BMI. The present study reports data by weight category as opposed to BMI.

The present study has several limitations. First, the retrospective nature of the study is subject to the inherent bias of retrospective work. Second, underdosed patients weighing greater than 120 kg may have been predisposed to adverse conditions due to morbidity associated with obesity rather than inadequate dosing of cefazolin. Third, despite having more than 17,000 patients, we may still be underpowered given the low rate of PJI. Fourth, the present study encompasses a large time-period and there may be protocol changes over this time-period that may not be accounted for. Fifth, while our study primarily focuses on weight, other factors that influence antibiotic dosing such as liver and kidney function, gender, and fat distribution were not considered. However, despite the aforementioned limitations, the present study does bring to light important dosing considerations when treating patients weighing 120 kg or more.

Perioperative antibiotics remain an important strategy in protection against PJI, one of the most devastating complications following TJA. While the majority of patients remain adequately dosed, underdosing of cefazolin in the obese patient is common. We suggest orthopaedic surgeons incorporate proper weight based antibiotic dosing in their preoperative planning. Orthopaedic surgeons must be vigilant when treating patients weighing 120 kg or greater as failure to adequately dose their perioperative antibiotics can unnecessarily predispose this population to PJI.

REFERENCES

- [1] Alijanipour P, Heller S, Parvizi J. Prevention of periprosthetic joint infection: what are the effective strategies? *J Knee Surg* 2014;27:251–8. doi:10.1055/s-0034-1376332.
- [2] Hansen E, Belden K, Silibovsky R, Vogt M, Arnold WV, Bicanic G, et al. Perioperative antibiotics. *J Arthroplasty* 2014;29:29–48. doi:10.1016/j.arth.2013.09.030.
- [3] Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Surg Infect* 2013;14:73–156. doi:10.1089/sur.2013.9999.
- [4] Kheir MM, Tan TL, Azboy I, Tan DD, Parvizi J. Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin. *Clin Orthop* 2017;475:1767–74. doi:10.1007/s11999-017-5302-0.
- [5] Flegal KM. Epidemiologic aspects of overweight and obesity in the United States. *Physiol Behav* 2005;86:599–602. doi:10.1016/j.physbeh.2005.08.050.
- [6] Pai MP, Bearden DT. Antimicrobial Dosing Considerations in Obese Adult Patients. *Pharmacother J Hum Pharmacol Drug Ther* 2007;27:1081–91. doi:10.1592/phco.27.8.1081.
- [7] Zmistowski B, Della Valle C, Bauer TW, Malizos KN, Alavi A, Bedair H, et al. Diagnosis of periprosthetic joint infection. *J Arthroplasty* 2014;29:77–83. doi:10.1016/j.arth.2013.09.040.
- [8] AlBuhairan B, Hind D, Hutchinson A. Antibiotic prophylaxis for wound infections in total joint arthroplasty: a systematic review. *J Bone Joint Surg Br* 2008;90:915–9. doi:10.1302/0301-620X.90B7.20498.
- [9] Tan TL, Gomez MM, Kheir MM, Maltenfort MG, Chen AF. Should Preoperative Antibiotics Be Tailored According to Patient's Comorbidities and Susceptibility to Organisms? *J Arthroplasty* 2017;32:1089–1094.e3. doi:10.1016/j.arth.2016.11.021.
- [10] Hansen E, Belden K, Silibovsky R, Vogt M, Arnold W, Bicanic G, et al. Perioperative antibiotics. *J Orthop Res Off Publ Orthop Res Soc* 2014;32 Suppl 1:S31–59. doi:10.1002/jor.22549.
- [11] Bratzler DW, Houck PM, Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Am J Surg* 2005;189:395–404. doi:10.1016/j.amjsurg.2005.01.015.
- [12] Neu HC. Cephalosporin antibiotics as applied in surgery of bones and joints. *Clin Orthop* 1984;50–64.
- [13] American Academy of Orthopaedic Surgeons; Information statement: recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthroplasty. AAOS n.d.
- [14] WHO | Global guidelines on the prevention of surgical site infection. WHO n.d. <http://www.who.int/gpsc/ssi-prevention-guidelines/en/> (accessed November 19, 2017).
- [15] Leaper D, Burman-Roy S, Palanca A, Cullen K, Worster D, Gautam-Aitken E, et al. Prevention and treatment of surgical site infection: summary of NICE guidance. *BMJ* 2008;337:a1924.

- [16] Guidelines Library | Infection Control | CDC n.d.
<https://www.cdc.gov/infectioncontrol/guidelines/index.html> (accessed November 19, 2017).
- [17] Pan S-D, Zhu L-L, Chen M, Xia P, Zhou Q. Weight-based dosing in medication use: what should we know? *Patient Prefer Adherence* 2016;10:549–60. doi:10.2147/PPA.S103156.
- [18] Ho VP, Nicolau DP, Dakin GF, Pomp A, Rich BS, Towe CW, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. *Surg Infect* 2012;13:33–7. doi:10.1089/sur.2010.097.
- [19] Meehan J, Jamali AA, Nguyen H. Prophylactic antibiotics in hip and knee arthroplasty. *J Bone Joint Surg Am* 2009;91:2480–90. doi:10.2106/JBJS.H.01219.
- [20] Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. *JAMA* 2016;315:2284–91. doi:10.1001/jama.2016.6458.
- [21] Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am* 2007;89:780–5. doi:10.2106/JBJS.F.00222.
- [22] Edmiston CE, Krepel C, Kelly H, Larson J, Andris D, Hennen C, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? *Surgery* 2004;136:738–47. doi:10.1016/j.surg.2004.06.022.
- [23] Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. *Surgery* 1989;106:750–6; discussion 756–757.
- [24] Sharareh B, Sutherland C, Pourmand D, Molina N, Nicolau DP, Schwarzkopf R. Effect of Body Weight on Cefazolin and Vancomycin Trabecular Bone Concentrations in Patients Undergoing Total Joint Arthroplasty. *Surg Infect* 2016;17:71–7. doi:10.1089/sur.2015.067.
- [25] Manrique J, Chen AF, Gomez MM, Maltenfort MG, Hozack WJ. Surgical site infection and transfusion rates are higher in underweight total knee arthroplasty patients. *Arthroplasty Today* 2017;3:57–60. doi:10.1016/j.artd.2016.03.005.

Table 1: Demographic information and dosing information

Cohort (n= 17,393)			
	Adequately Dosed (n=14,537)	Underdosed (n=2,856)	<i>P value</i>
Age (year)	63.5 (0.09)	63.5 (0.22)	0.849
Gender (male)	6417 (44.1%)	1736 (60.8%)	<0.001
BMI	29.55 (0.04)	32.11 (0.13)	<0.001
Weight (kg)	84.41 (0.14)	97.17 (0.49)	<0.001
CCI	0.391 (0.01)	0.386 (0.02)	<0.001
Joint (knee)	6895 (47.4%)	1320 (46.2%)	0.235
LOS	2.67 (0.02)	3.05 (0.05)	<0.001
90 day Readmission	555 (3.8%)	128 (4.5%)	0.113
1-year PJI	125 (0.86%)	43 (1.51%)	0.002
Stratified by Weight			
	< 120 kg (n=16,409)	≥ 120 kg (n=984)	<i>P value</i>
Age (year)	63.9 (0.09)	57.8 (0.29)	0.039
CCI	0.387 (0.01)	0.441 (0.03)	0.100
Joint (knee)	8047 (46.6%)	567 (57.8%)	<0.001
LOS	2.71 (0.02)	3.11 (0.08)	0.618
90 day Readmission	614 (3.7%)	69 (7.0%)	<0.001
Underdosed	1912 (11.7%)	944 (95.9%)	<0.001
1-year PJI	136 (0.83%)	32 (3.25%)	<0.001

Data presented in table as mean (standard error) or number (percentage)

Abbreviations: BMI, Body Mass Index; kg, kilogram; CCI, Charlson Comorbidity index; LOS, Length of Stay; PJI, Periprosthetic Joint Infection

Table 2: Bivariate analysis of Cefazolin and 1-year PJI

	Adjusted Odds Ratio	<i>P Value</i>
Underdosed	1.762	0.002
Gender (male)	1.517	0.014
Joint (knee)	0.900	0.512
Younger Age (year)	1.010	0.174
Weight (kg)	1.025	<0.001
BMI	1.080	<0.001
CCI	1.251	<0.001

Abbreviations: PJI, Periprosthetic Joint Infection; kg, kilogram; BMI, Body Mass Index; CCI, Charlson Comorbidity index

Table 3: Multivariate analysis for weight-based dosing of Cefazolin and likelihood of PJI

Regression		
	Adjusted Odds Ratio	<i>P Value</i>
Underdosed	1.665	0.006
Gender (male)	1.372	0.067
Younger Age (year)	1.011	0.130
CCI	1.259	<0.001

Abbreviations: PJI, Periprosthetic Joint Infection; kg, kilogram; CCI, Charlson Comorbidity index